Skip to main content
Fig. 1 | Gut Pathogens

Fig. 1

From: Efficacy of tailored second-line therapy of Helicobacter pylori eradication in patients with clarithromycin-based treatment failure: a multicenter prospective study

Fig. 1

Flow chart of the study design LEV levofloxacin, TBQT tailored, bismuth-based quadruple therapy, amoxicillin (1000 mg twice daily) + levofloxacin (500 mg once daily) or furazolidone (100 mg twice daily) + esomeprazole (20 mg twice daily) + colloidal bismuth pectin (220 mg twice daily), LBQT levofloxacin- and bismuth-based quadruple therapy, amoxicillin (1000 mg twice daily) + levofloxacin (500 mg once daily) + esomeprazole (20 mg twice daily) + colloidal bismuth pectin (220 mg twice daily); ALEB: amoxicillin (1000 mg twice daily) + levofloxacin (500 mg once daily) + esomeprazole (20 mg twice daily) + colloidal bismuth pectin (220 mg twice daily); AFEB: amoxicillin (1000 mg twice daily) + furazolidone (100 mg twice daily) + esomeprazole (20 mg twice daily) + colloidal bismuth pectin (220 mg twice daily), ITT, intention-to-treat, PP per protocol

Back to article page
\